

## SUPPLEMENTARY TABLES

**Supplementary Table 1. Relationship between circRNA Cdr1as expression and clinicopathological characteristics of hepatocellular carcinoma patients.**

Clinicopathological characteristics	n	High expression	Low expression	P value
<b>Total</b>	42	21	21	
<b>Gender</b>				1.000
Male	30	15	15	
Female	12	6	6	
<b>Age (years)</b>				0.758
≤54	20	11	9	
>54	22	10	12	
<b>Grade of differentiation</b>				0.589
Low	17	9	8	
Middle	15	6	9	
High	10	6	4	
<b>Tumor diameter (cm)</b>				<b>0.012*</b>
≤5	19	5	14	
>5	23	16	7	
<b>Liver function (Child-Pugh stage)</b>				1.000
A	35	17	18	
B or C	7	4	3	
<b>Hepatocirrhosis</b>				0.719
Absent	10	6	4	
Present	32	15	17	
<b>HBV infection</b>				0.520
Absent	15	9	6	
Present	27	12	15	
<b>AFP (ng/ml)</b>				<b>0.005*</b>
≤20	20	5	15	
>20	22	16	6	
<b>Tumor satellite</b>				<b>0.033*</b>
Absent	31	12	19	
Present	11	9	2	

Two-sided  $\chi^2$  or Fisher's exact test for all variables between Low expression group and High expression group, \* $P < 0.05$ .

**Supplementary Table 2. The potential miRNAs binding to circRNA Cdr1as through bioinformatics prediction.**

<b>RegRNA</b>	<b>Circular RNA Interactome</b>	<b>Intersection</b>
hsa-miR-7-5p	hsa-miR-1180	<b>hsa-miR-671-5p</b>
<b>hsa-miR-671-5p</b>	hsa-miR-1231	<b>hsa-miR-1270</b>
<b>hsa-miR-1270</b>	hsa-miR-1243	
hsa-miR-3156-5p	hsa-miR-1246	
	hsa-miR-1277	
	hsa-miR-1287	
	hsa-miR-1290	
	hsa-miR-1299	
	hsa-miR-1304	
	hsa-miR-203	
	hsa-miR-21	
	hsa-miR-590-5p	
	hsa-miR-432	
	hsa-miR-490-5p	
	hsa-miR-516b	
	hsa-miR-576-3p	
	hsa-miR-619	
	hsa-miR-1270	
	hsa-miR-620	
	hsa-miR-647	
	hsa-miR-671-5p	
	hsa-miR-7	
	hsa-miR-873	
	hsa-miR-890	
	hsa-miR-944	